Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma

Table 2 Phase III clinical trials testing antiangiogenic tyrosine kinase inhibitors in combination with chemotherapy in non-small cell lung cancer

Trial	n	Study design	PE	OS (mo)	PFS (mo)	ORR (%)
Vandetanib second-line
ZEAL[103]	534	PV vs P	PFS	10.5 vs 9.2	17.6 wk vs 11.9 wk	19 vs 8
ZEST[104]	1240	EV vs E	PFS	6.9 vs 7.8	2.6 vs 2.0	12 vs 12
ZODIAC[105]	1391	DV vs D	PFS	10.6 vs 10.0	4.0 vs 3.2	NA
Vandetanib second or third-line
ZEPHYR[106]	924	V vs placebo	OS	8.5 vs 7.8	NA	2.6 vs 0.7
Sorafenib first-line
NEXUS[107]	904	G + Cis + S f/b S vs G + Cis f/b placebo	OS	376 d vs 379 d	183 d vs 168 d	28 vs 26
Motesanib first-line
MONET[6]	1090	PC + M vs PC	OS	13.0 vs 11.0	5.6 vs 5.4	40 vs 26
Cediranib first-line
BR29 (active, no longer recruiting, NCT00795340)	750	PC + Ced vs PC	OS	NA	NA	NA
Nintedanib second-line
LUME-Lung 1 (active, no longer recruiting, NCT00805194)	1300	D + Nin vs D	PFS	NA	NA	NA
LUME-Lung 2 (active, no longer recruiting, NCT00806819)	1302	P + Nin vs P	PFS	NA	NA	NA

PC: Paclitaxel and carboplatin; P: Pemetrexed; E: Erlotinib; D: Docetaxel; V: Vandetanib; DV: Docetaxel-vandetanib; EV: Erlotinib-vandetanib; G: Gemcitabine; Cis: Cisplatin; S: Sorafenib; f/b: Followed by; M: Motesanib; Ced: Cediranib; Nin: Nintedanib; OS: Overall survival; PE: Primary endpoint; PFS: Progression-free survival; ORR: Objective response rate; NSCLC: Non-small cell lung cancer; NA: Not available.